Adult Dosing
Bacterial infections caused by susceptible bacteria
- Serious infections: 150-300 mg PO qid; 300-450 mg PO qid in more severe infections
Pharyngitis (Acute)[Non-FDA Approved]
Malaria [Non FDA-Approved]
- 20mg base/kg/day PO divided tid x 7 days [Max 600 mg/dose]
Pediatric Dosing
Bacterial infections caused by susceptible bacteria
- Serious infections: CAPS: 8-16 mg/kg/day PO divided tid-qid; SOLN: 8-12 mg/kg/day PO divided tid-qid; Max: 1.8 g/day
- Severe infections: CAPS: 16-20 mg/kg/day PO divided tid-qid; SOLN: 17-25 mg/kg/day PO divided tid-qid Max: 1.8 g/day
- In cases of beta-hemolytic streptococcal infections, treat for at least 10 days
Cellulitis [Non-FDA Approved]
- 10-30 mg/kg/24 hr divided q6-8hr
Pharyngitis (Acute)[Non-FDA Approved]
- 21 mg/kg/day PO, divided tid [Max 900 mg/day]
Malaria [Non FDA-Approved]
- 20mg base/kg/d PO divided tid x 7 days [Max 600 mg/dose]
[Outline]
- Serious infections caused by susceptible strains of anaerobic bacteria (streptococci, pneumococci and staphylococci)
Note Reserve for penicillin-allergic patients or for patients in whom penicillin is considered inappropriate
- Mild diarrhea to life threatening colitis associated with clostridium difficile may occur [US Black Box Warning]
- Used only to treat infections proven or strongly suspected to be caused by susceptible bacteria due to increased risk of development of drug-resistant bacteria. If superinfection occurs, institute appropriate therapy
- To reduce the development of drug-resistant bacteria susceptibility tests should be performed before starting therapy
- Maintain appropriate fluid and electrolyte levels, protein supplementation, along with antibiotics for C. difficile as needed
- Clindamycin does not diffuse adequately into the cerebrospinal fluid; use in meningitis is not recommended
- Concomitant erythromycin use not recommended
- Carefully monitor geriatric patients for change in bowel frequency
- Monitor patient for signs of anaphylaxis or allergic reactions; discontinue therapy if serious reactions occur
- Monitor LFTs in severe hepatic impairment; BUN/serum creatinine, CBC if prolonged therapy
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
- GI disease particularly colitis
- Asthma
- Atopic individuals
- History of antibiotic-associated colitis
Pregnancy Category:B
Breastfeeding: Possibly unsafe; may cause adverse effects on the breastfed infant's gastrointestinal flora. Monitor infants for diarrhea, candidiasis or colitis. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT). This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed 5 October 2010). Manufacturer advises to use this drug only if clearly needed.
Pricing data from www.DrugStore.com in U.S.A.
- Cleocin 75 MG/5ML SOLR [Bottle] (PFIZER U.S.)
100 5ml = $78.7
300 5ml = $198.46 - Cleocin 150 MG CAPS [Bottle] (PFIZER U.S.)
30 mg = $127.04
90 mg = $355.55
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
